Moderna Inc MRNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 3:23 PM EST

131.49

-15.31 (-10.43%)

Volume

11,596,356

52 week range

19.31 - 189.26

...

Loading . . .

KEY STATS

Open146.09
Day High147.32
Day Low131.11
Prev Close146.81
52 Week High189.26
52 Week High Date02/08/21
52 Week Low19.31
52 Week Low Date03/13/20
Market Cap52.568B
Shares Out399.77M
10 Day Average Volume10.71M
Dividend-
Dividend Yield-
Beta1.5
1 Year % Change376.68

RATIOS/PROFITABILITY

EPS (TTM)-1.94
P/E (TTM)-67.88
Fwd P/E (NTM)8.77
EBITDA (MRQ)-731.893M
ROE (MRQ)-39.99%
Revenue (MRQ)803.40M
Gross Margin (MRQ)70.05%
Net Margin (MRQ)-92.99%
Debt To Equity (MRQ)4.29%

EVENTS

Earnings Date05/05/2021
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest Moderna Inc News

3 Hours Ago

Cramer says post-Covid travel boom could be 'sky's the limit,' investors be ready CNBC.com

4 Hours Ago

Johnson & Johnson's Covid vaccine rolls out across the U.S., boosting supplies CNBC Video

CNBC.com

20 Hours Ago

J&J CEO on Merck vaccine deal: 'Extraordinary times take extraordinary efforts' CNBC.com

22 Hours Ago

Detroit expands Covid vaccine eligibility to autoworkers CNBC.com

March 2, 2021

Biden says Merck will help make Johnson & Johnson's Covid vaccine CNBC.com

Latest MRNA News From Our Partners

4 Hours Ago

Early March Vaccine Thoughts Seeking Alpha

23 Hours Ago

Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon Seeking Alpha

March 2, 2021

Moderna to seek Japanese approval for COVID-19 vaccine later this week Seeking Alpha

March 2, 2021

Moderna to seek Japanese approval for COVID-19 vaccine later this week Seeking Alpha

March 2, 2021

Wall Street Breakfast: A Greener World Seeking Alpha

QUOTE FINDER

Market Movers

Profile

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced...

Noubar Afeyan Ph.D.

Non-Executive Chairman

Stephane Bancel

Chief Executive Officer

Stephen Hoge M.D.

President

David Meline

Chief Financial Officer

Juan Andres

Chief Technology Officer

Lori Henderson J.D.

General Counsel

Address

200 Technology Sq

Cambridge, MA

02139-3578

United States

https://www.modernatx.com/

Moderna Inc MRNA:NASDAQ

KEY STATS

RATIOS/PROFITABILITY

EVENTS

QUOTE FINDER

Related Video

Profile